Coya Therapeutics, Inc. (COYA)
NASDAQ: COYA · Real-Time Price · USD
6.41
+0.24 (3.89%)
At close: Feb 21, 2025, 4:00 PM
6.40
-0.01 (-0.16%)
After-hours: Feb 21, 2025, 4:54 PM EST
Coya Therapeutics Revenue
Coya Therapeutics had revenue of $9.55M in the twelve months ending September 30, 2024. In the year 2023, Coya Therapeutics had annual revenue of $6.00M.
Revenue (ttm)
$9.55M
Revenue Growth
n/a
P/S Ratio
9.33
Revenue / Employee
$1,194,289
Employees
8
Market Cap
107.09M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 6.00M | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCOYA News
- 15 days ago - Coya Therapeutics Now Pivots Toward Phase 2 In ALS And FTD - Seeking Alpha
- 15 days ago - Coya: A Few Catalysts On The Way For COYA-302 Makes This A Must Watch - Seeking Alpha
- 16 days ago - Coya Therapeutics' Alzheimer's Candidate Shows Improved Inflammatory Blood Markers Following Monthly Dosing - Benzinga
- 16 days ago - Coya Therapeutics Reports Statistically Significant Improvement of Inflammatory Blood Markers in Patients with Alzheimer's Disease Following Monthly Dosing with Low-Dose IL-2, Further Supporting Clinical Development - Business Wire
- 18 days ago - Coya Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - Business Wire
- 4 weeks ago - Coya Therapeutics Announces Pipeline Expansion - COYA 303: COYA 301 in Combination with GLP-1 Receptor Agonist for the Treatment of Inflammatory Diseases - Business Wire
- 2 months ago - Coya Therapeutics Provides Enrollment Update of the Investigator-Initiated Phase 1 Study of Low Dose Interleukin-2 (LD IL-2) + CTLA4-Ig Fusion Protein in Patients with Frontotemporal Dementia (FTD) - Business Wire
- 3 months ago - Coya Therapeutics to Participate in a Fireside Chat at the 7th Annual Evercore HealthCONx Conference - Business Wire